FDA approved in May 2018, limited availability June 2018 with broader commercial launch in early 2019
Cost, $3,300 per 100 mg vial
Andexanet alfa
Ecallantide
Insulin
Desmopressin
Antivenin
Ondansteron
Octreotide
Montelukast